Lantheus Holdings, Inc. (NASDAQ:LNTH) Holdings Cut by Granite Investment Partners LLC

Granite Investment Partners LLC decreased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 24.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 60,665 shares of the medical equipment provider's stock after selling 19,130 shares during the period. Granite Investment Partners LLC owned 0.09% of Lantheus worth $4,871,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Benjamin F. Edwards & Company Inc. purchased a new position in shares of Lantheus during the 2nd quarter worth about $80,000. Intech Investment Management LLC purchased a new position in Lantheus during the second quarter worth approximately $1,235,000. Resolute Capital Asset Partners LLC boosted its holdings in shares of Lantheus by 125.0% in the 2nd quarter. Resolute Capital Asset Partners LLC now owns 90,000 shares of the medical equipment provider's stock valued at $7,226,000 after purchasing an additional 50,000 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Lantheus during the 2nd quarter valued at $313,000. Finally, Seven Eight Capital LP acquired a new stake in shares of Lantheus during the 2nd quarter worth $1,523,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on LNTH shares. B. Riley boosted their price target on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research report on Thursday, July 25th. Redburn Atlantic began coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price for the company. Truist Financial cut their price target on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a report on Thursday, August 1st. JMP Securities decreased their price objective on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research note on Thursday, August 1st. Finally, Leerink Partners raised their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Thursday, July 11th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

Insider Buying and Selling

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the stock in a transaction on Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now directly owns 62,216 shares in the company, valued at approximately $7,661,900.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now owns 98,980 shares in the company, valued at approximately $9,540,682.20. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the company's stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the sale, the chief accounting officer now directly owns 62,216 shares in the company, valued at $7,661,900.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,852 shares of company stock worth $3,922,001. Insiders own 1.50% of the company's stock.

Lantheus Stock Up 1.4 %

LNTH traded up $1.49 during trading hours on Friday, reaching $110.05. 1,162,276 shares of the stock traded hands, compared to its average volume of 1,020,474. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a market cap of $7.63 billion, a price-to-earnings ratio of 16.80 and a beta of 0.50. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The firm's fifty day simple moving average is $105.51 and its two-hundred day simple moving average is $84.24.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm's revenue was up 22.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.40 earnings per share. As a group, analysts forecast that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.